You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for LIMKi 3
LIMKi 3 is a potent LIM kinase inhibitor (IC50 values are 7 and 8 nM for LIMK1 and LIMK2 respectively). Inhibits cofilin phosphorylation in MDA-MB-231 breast cancer cells. Reduces MDA-MB-231 tumor cell invasion in a 3D matrigel invasion assay.
Compound Libraries for LIMKi 3
Technical Data for LIMKi 3
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for LIMKi 3
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for LIMKi 3
The following data is based on the product molecular weight 431.29. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.32 mL||11.59 mL||23.19 mL|
|5 mM||0.46 mL||2.32 mL||4.64 mL|
|10 mM||0.23 mL||1.16 mL||2.32 mL|
|50 mM||0.05 mL||0.23 mL||0.46 mL|
References for LIMKi 3
References are publications that support the biological activity of the product.
Ross-Macdonald et al (2008) Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors. Mol.Cancer Ther. 7 3490 PMID: 19001433
Scott et al (2010) LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells. J.Cell Biol. 191 169 PMID: 20876278
Sparrow et al (2012) The actin-severing protein cofilin is downstream of neuregulin signaling and is essential for Schwann cell myelination. J.Neurosci. 32 5284 PMID: 22496574
If you know of a relevant reference for LIMKi 3, please let us know.
View Related Products by Product Action
Keywords: LIMKi 3, LIMKi 3 supplier, LIMKi3, potent, lim, kinases, inhibitors, inhibits, antitumor, BMS5, BMS, 5, LIMK, 4745, Tocris Bioscience
1 Citation for LIMKi 3
Citations are publications that use Tocris products. Selected citations for LIMKi 3 include:
Georgouli et al (2019) Regional Activation of Myosin II in Cancer Cells Drives Tumor Progression via a Secretory Cross-Talk with the Immune Microenvironment. Cell 176 757 PMID: 30712866
Do you know of a great paper that uses LIMKi 3 from Tocris? Please let us know.
Reviews for LIMKi 3
There are currently no reviews for this product. Be the first to review LIMKi 3 and earn rewards!
Have you used LIMKi 3?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cell Cycle & DNA Damage Repair Poster
In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.